



Quinidine (1.BB.935): sc-71949

BACKGROUND

Quinidine is a class I antiarrhythmic agent first obtained from the bark of the cinchona tree. It is a stereoisomer of quinine that functions by blocking the fast inward sodium current, causing the phase 0 depolarization of the cardiac action potential to decrease, and prolonging the cardiac action potential, thereby prolonging the QT interval on the surface EKG. Quinidine also blocks the slowly inactivating tetrodotoxin-sensitive sodium current, the slow inward calcium current, the rapid and slow components of the delayed potassium rectifier current, the inward potassium rectifier current and the ATP-sensitive potassium channel. Quinidine inhibits the cytochrome P450 enzyme 2D6 and it may lead to increased blood levels of lidocaine, β -blockers, opioids and some antidepressants. Quinidine has a half life of six to eight hours and is metabolized in the liver by the cytochrome P450 system.

REFERENCES

1. Yeh, J.Z. and Narahashi, T. 1976. Mechanism of action of Quinidine on squid axon membranes. *J. Pharmacol. Exp. Ther.* 196: 62-70.
2. Salata, J.J. and Wasserstrom, J.A. 1988. Effects of Quinidine on action potentials and ionic currents in isolated canine ventricular myocytes. *Circ. Res.* 62: 324-337.
3. Nattel, S. and Quantz, M.A. 1989. Pharmacological response of Quinidine induced early after depolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. *Cardiovasc. Res.* 22: 808-817.
4. Undrovinas, A.I., Burnashev, N., Eroshenko, D., Fleidervish, I., Starmer, C.F., Makielski, J.C. and Rosenshtraukh, L.V. 1990. Quinidine blocks adenosine 5'-triphosphate-sensitive potassium channels in heart. *Am. J. Physiol.* 259: H1609-H1612.
5. Von Moltke, L.L., Greenblatt, D.J., Cotreau-Bibbo, M.M., Harmatz, J.S. and Shader, R.I. 1994. Inhibitors of alprazolam metabolism *in vitro*: effect of serotonin-reuptake-inhibitor antidepressants, Ketoconazole and Quinidine. *Br. J. Clin. Pharmacol.* 38: 23-31.
6. Anyukhovsky, E.P., Sosunov, E.A., Feinmark, S.J. and Rosen, M.R. 1998. Effects of Quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: II. *In vivo* study. *Circulation* 96: 4019-4026.
7. Darbar, D., Fromm, M.F., Dellorto, S. and Roden, D.M. 2001. Sympathetic activation enhances QT prolongation by Quinidine. *J. Cardiovasc. Electrophysiol.* 12: 9-14.
8. Mathis, A.S. and Gandhi, A.J. 2002. Serum Quinidine concentrations and effect on QT dispersion and interval. *Ann. Pharmacother.* 36: 1156-1161.
9. Appel, S.B., Liu, Z., McElvain, M.A. and Brodie, M.S. 2003. Ethanol excitation of dopaminergic ventral tegmental area neurons is blocked by Quinidine. *J. Pharmacol. Exp. Ther.* 306: 437-446.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

SOURCE

Quinidine (1.BB.935) is a mouse monoclonal antibody raised against Quinidine.

PRODUCT

Each vial contains 100 μ g IgG_{2b} in 1.0 ml PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Quinidine (1.BB.935) is recommended for detection of Quinidine by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.